3 Stocks Advancing The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 87 points (0.5%) at 16,606 as of Thursday, May 8, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,938 issues advancing vs. 1,065 declining with 159 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.5%. Top gainers within the industry include Biogen Idec ( BIIB), up 2.0%, Alexion Pharmaceuticals ( ALXN), up 1.5% and Regeneron Pharmaceuticals ( REGN), up 1.1%. On the negative front, top decliners within the industry include Merck ( MRK), down 1.3%, Valeant Pharmaceuticals International ( VRX), down 0.9%, Actavis ( ACT), down 0.9% and Allergan ( AGN), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Abbott Laboratories ( ABT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.21 (0.5%) to $38.90 on light volume. Thus far, 2.0 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.9 million shares. The stock has ranged in price between $38.55-$38.96 after having opened the day at $38.69 as compared to the previous trading day's close of $38.69.

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $59.5 billion and is part of the health care sector. Shares are up 0.9% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including deteriorating net income and relatively poor performance when compared with the S&P 500 during the past year. Get the full Abbott Laboratories Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Celgene ( CELG) is up $1.26 (0.9%) to $146.51 on light volume. Thus far, 1.1 million shares of Celgene exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $144.41-$147.77 after having opened the day at $144.97 as compared to the previous trading day's close of $145.25.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $58.7 billion and is part of the health care sector. Shares are down 14.0% year-to-date as of the close of trading on Wednesday. Currently there are 23 analysts who rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $0.97 (1.2%) to $79.74 on average volume. Thus far, 7.6 million shares of Gilead exchanged hands as compared to its average daily volume of 17.0 million shares. The stock has ranged in price between $78.59-$80.28 after having opened the day at $78.88 as compared to the previous trading day's close of $78.77.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $120.4 billion and is part of the health care sector. Shares are up 4.9% year-to-date as of the close of trading on Wednesday. Currently there are 18 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Stocks Dive Globally as U.S.-China Trade War Intensifies

Stocks Dive Globally as U.S.-China Trade War Intensifies

Global Oil Prices Mixed as OPEC Production Talks, China Tariffs Weigh on Markets

Global Oil Prices Mixed as OPEC Production Talks, China Tariffs Weigh on Markets

Cryptocurrencies Could 'Bring the Internet to a Halt', Central Bank Agency Warns

Cryptocurrencies Could 'Bring the Internet to a Halt', Central Bank Agency Warns

Volkswagen's Audi CEO Arrested in Diesel Emissions Probe

Volkswagen's Audi CEO Arrested in Diesel Emissions Probe

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know